CEACAM5 and neoplasm: Identification of CEACAM1 as a MHC-I-independent NK inhibitory receptors provided new insights toward understanding tumor immune evasion mechanisms [17], since the binding partners of CEACAM1—CEACAM1 itself and CEACAM5—are widely present in various types of cancers.